T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

SEATTLE - Atossa Therapeutics, Inc. (NASDAQ:ATOS), a biopharmaceutical company focusing on breast cancer treatment with a market capitalization of $107 million, has encountered a challenge in its ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The use of radiation therapy has become a staple in breast cancer treatment, with benefits seen in node-positive patients, those with locally advanced disease, and those with large-sized tumors.

VALLEY — Narfunda Ross was the guest speaker at Monday’s meeting of the Valley Lions Club, held at San Marcos Restaurant. She talked about her personal experience as a breast cancer survivor and the ...

Katrina Cooke and Ashley Dostefano share their personal journeys, reflecting on the challenges they faced, the victories they ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Alaska has a low breast cancer screening rate. So, a few businesses offer evening parties with food and drink, where friends ...

The University of Iowa study is analyzing the period between breast cancer diagnosis and treatment, when many patients feel ...

Several new treatment options for patients with breast cancer have emerged over the last few years, including more oral ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...